[go: up one dir, main page]

WO2013109142A1 - Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie - Google Patents

Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie Download PDF

Info

Publication number
WO2013109142A1
WO2013109142A1 PCT/NL2013/050021 NL2013050021W WO2013109142A1 WO 2013109142 A1 WO2013109142 A1 WO 2013109142A1 NL 2013050021 W NL2013050021 W NL 2013050021W WO 2013109142 A1 WO2013109142 A1 WO 2013109142A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
disclosed
erk
braf
pdk
Prior art date
Application number
PCT/NL2013/050021
Other languages
English (en)
Inventor
Daniel Simon Peeper
Joanna KAPLON
Original Assignee
Stichting Het Nederlands Kanker Instituut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Het Nederlands Kanker Instituut filed Critical Stichting Het Nederlands Kanker Instituut
Publication of WO2013109142A1 publication Critical patent/WO2013109142A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the current disclosure relates to the field of treating neoplasia in subject in need thereof, in particular neoplasia that involve (activated) MAPK/ERK pathway proteins, like BRAF melanomas and the like.
  • Cancer malignant neoplasm, is a heterogeneous group of conditions characterized by abnormal proliferation of cells (neoplasia). Cancer is a leading cause of death.
  • Skin neoplasm relates to neoplasia of cell originating from the skin.
  • Melanoma is, next to basal cell cancer and squamous cell cancer, one of the three most serious types of skin cancer.
  • Skin cancer is the most commonly diagnosed type of cancer.
  • melanoma causes the majority (75%) of deaths related to skin cancer (Jerant et al 2000 Am Fam Physician 62 (2): 357-68, 375-6, 381-2). Worldwide, about 160,000 new cases of melanoma are diagnosed yearly. It occurs more frequent in women than in men and is particularly common among Caucasians living in sunny climates, with high rates of incidence in Australia, New Zealand, North America, Latin America, and northern Europe (Parkin et al 2005 CA Cancer J Clin 55 (2): 74-108). According to a WHO report, melanoma cause about 48,000 deaths worldwide per year
  • the first sign of melanoma often is a change in size, shape, color or feel of a mole, which may accordingly have turned into a malignant tumor of melanocytes.
  • Melanocytes are cells that normally produce the pigment melanin, which is responsible for brownish tint of skin. They predominantly occur in skin, but are also found in other parts of the body, such as in the bowel and the eye (uveal melanoma). Melanoma can occur in any part of the body where melanocytes are present.
  • the treatment typically includes surgical removal of the melanoma, adjuvant treatment, chemo- and immunotherapy, and/or radiation therapy. The chance of a cure is greatest when the melanoma is discovered while it is still small and thin, and can be removed entirely. Approximately 40-60% of (cutaneous) melanomas carry a mutation in a specific protein kinase referred to as BRAF.
  • This pathway plays a significant role in modulating cellular responses to extracellular stimuli, particularly in response to growth factors, and the pathway controls cellular events including cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis (Peyssonnaux et al., Biol Cell. 93(l-2):53-62 (2001)).
  • the MAPK pathway is activated as follows.
  • RAS receptor-ligand binding results in cytoplasmic BRAF protein being localized to the intracellular membrane surface by binding directly to RAS (Jaiswal et al., Mol Cell Biol. 14(10):6944- 53 (1994)), which, in turn, results in BRAF phosphorylation.
  • BRAF serine/threonine kinase activity is activated and the activated enzyme phosphorylates MEK, which is also referred to as MAPKK.
  • MEK phosphorylation activates its kinase activity, and it in turn phosphorylates ERK, which is also referred to as MAPK.
  • ERK Upon phosphorylation, ERK is translocated into the nucleus, where it phosphorylates transcription factors and thereby stimulates transcription of various genes involved in cell growth, differentiation and apoptosis (Peyssonnaux et al, Biol Cell. 93 (1-2) -.53-62 (2001)).
  • the pathway includes many other proteins, next to the above-mentioned MAPK (originally called ERK), BRAF and MEK (MAPKK).
  • MAPK originally called ERK
  • BRAF BRAF
  • MEK MEK
  • the latter one are examples of proteins that communicate by adding phosphate groups to a neighboring protein, which acts as an "on” or "off switch in the MAPK/ERK pathway.
  • the MAPR/ERK pathway is dysregulated (see also Flaherty 201 1 : Nature Reviews: Drug Discovery 10:811), for example one or more of the proteins in the pathway may be mutated, leading the protein to be stuck in the "on" or “off position.
  • mutated BRAF proteins typically have elevated kinase activity and as such may cause uncontrolled activation of the MAPK pathway, leading to uncontrolled proliferation of malignant tumor cells.
  • the other components of the MAPK/ERK pathway are considered as important targets in attempts to control cancers (e.g. see Poulikakos et al.
  • PLX4032 Vemurafenib
  • PLX4032 is a potent inhibitor of mutated BRAF (Bollag et al Nature 2010;467:596-9).
  • PLX4032 has remarkable clinical activity in patients with melanomas that contain the V600E mutation in BRAF (Flaherty et al N Engl J Med 2010; 363:809-19).
  • responses to a BRAF inhibitor such as PLX4032 are temporary, and typically resistance to PLX4032 develops over time (reviewed in Solit et al. 201 1 ; N Engl J Med 364:8, and see also Flaherty 2011 : Nature Reviews: Drug Discovery 10:811)).
  • the following terms have the meanings ascribed to them below, unless specified otherwise.
  • the term "and/or" indicates indicate that one or more of the stated cases may occur. In other words, a stated case may either occur alone or in combination with at least one of the stated cases, up to with all of the stated cases.
  • alteration is meant a change (increase or decrease) in the expression levels of a polynucleotide or polypeptide, or activity of the protein as detected by standard art known methods such as those described above.
  • an alteration includes a 5% or 10% change, a 25% change, a 40% change, a 50%, a 100% change, or greater change, or any change within the range of the values provided.
  • amelioration refers to a reduction of at least one sign and/or symptom of a specific disease or condition.
  • Treatment refers to reduction of at least one sign and/or symptom of a disease or condition to reduce or eliminate at least one sign and/or symptom of the disease or condition, or to prevent or delay progression of the disease or condition.
  • Amelioration and treatment need not be considered separate interventions, but instead can be considered a continuum of therapeutic interventions.
  • “Beneficial results” may include, but are in no way limited to, lessening or alleviating the severity of the disease condition, preventing the disease condition from worsening, curing the disease condition and prolonging a patient's life or life expectancy.
  • the disease conditions may relate to or may be modulated by the central nervous system.
  • Cancer and “cancerous”, as used herein, refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Cancer is also referred to as malignant neoplasm.
  • control reference sample As used herein, "changed as compared to a control reference sample” is understood as having a level or activity of an analyte, or in a whole organism change of physical
  • Control samples typically include a cell or an animal of the same type that has not been contacted with an active agent or been subjected to a particular treatment, and has optionally been contacted with a carrier or subjected to a sham treatment. Control samples also include a cell or an animal not subjected to an agent or treatment to induce a specific disease or condition.
  • “Chemotherapy” refers to the use of chemicals, such as pharmaceuticals or drugs, in the treatment of a disease condition, such as cancer.
  • “Chemotherapeutic agents” denote particular chemicals, such as pharmaceuticals or drugs, which are used to effect chemotherapy.
  • the phrase "in combination with” is intended to refer to all forms of administration that provide a first agent together with a second agent, such as a second inhibitory molecule or a chemotherapeutic agent, where the two are administered concurrently or sequentially in any order.
  • a second agent such as a second inhibitory molecule or a chemotherapeutic agent
  • the agents need not be administered simultaneously or in the same formulation.
  • Agents administered in combination with each other simultaneously present or have biological activity in the subject to which the agents are delivered. Determination of the presence of a agent in a subject can be readily determined by empirical monitoring or by calculations using known
  • a therapeutic combination is understood as a combination of one or more active drug substances, i.e. compounds having a therapeutic utility.
  • each such compound in the therapeutic combinations will be present in a pharmaceutical composition comprising that compound and a pharmaceutically acceptable carrier.
  • the compounds in a therapeutic combination of the present invention may be administered simultaneously or separately, as part of a regimen
  • control is meant a standard or reference condition.
  • ⁇ decreases or “inhibit” or “lower” is meant a reduction by at least about 5% relative to a reference level. A decrease may be by 5%, 10%, 15%, 20%, 25% or 50%, or even by as much as 75%, 85%, 95% or more, or any change within the range of the values provided.
  • the terms “disease” or “condition” are commonly recognized in the art and designate the presence of at least one sign and/or symptom in a subject or patient that are generally recognized as abnormal. Diseases or conditions may be diagnosed and categorized based on pathological changes (e.g., hyperproliferation).
  • Signs may include any objective evidence of a disease such as changes that are evident by physical examination of a patient or the results of diagnostic tests that may include, among others, laboratory tests.
  • Symptoms are subjective evidence of disease or a patient condition, e.g., the patient's perception of an abnormal condition that differs from normal function, sensation, or appearance, which may include, without limitations, physical disabilities, morbidity, pain, and other changes from the normal condition experienced by a subject.
  • an effective amount is meant the amount of an agent required to ameliorate the symptoms of a disease relative to an untreated patient.
  • the effective amount of active agent(s) used to practice the present invention for therapeutic treatment of a neoplasia varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an "effective" amount.
  • the term effective amount refers to a dosage or amount that is sufficient to reduce, halt, or slow tumor progression to result in alleviation, lessening or amelioration of symptoms in a patient or to achieve a desired biological outcome, e.g., slow or stop tumor growth or reduction or disappearance of a tumor.
  • an agent which is "effective against” a disease or condition indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as an improvement of symptoms, a cure, a reduction in at least one disease sign or symptom, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating the particular type of disease or condition.
  • An agent can be effective against a specific disease or condition without being effective against the disease or condition for all subjects. Methods of selection of patient populations for treatment with the agents of the invention is an aspect of the invention.
  • the expression level is to be understood as the amount of RNA transcript that is transcribed by a gene and/or the amount of protein that may be translated from an RNA transcript, e.g. mRNA.
  • the expression level may be determined through quantifying the amount of RNA transcript which is expressed, e.g. using standard methods such as quantitative PCR of a mature miRNA, microarray, or Northern blot.
  • the expression level may also be determined through measuring the effect of a miRNA on a target mRNA.
  • a 3'UTR sequence comprising a target miRNA target sequence may be incorporated in a reporter gene, e.g.
  • the expression level of a miRNA gene may be indirectly measured by measuring the amount of Luciferase expression which may be controlled by a particular miRNA.
  • the amount of Luciferase expression also correlates with the expression level of the particular gene.
  • the expression level of the miRNA may be correlated to the expression level of a target gene of the particular miRNA.
  • the amount of protein that may be translated from an RNA transcript may also be measured to determine the expression level of a gene.
  • the expression level of a protein may also be indirectly measured.
  • a reporter gene construct may be used which comprises the RNA transcription factor binding site. The expression level may than be subsequently determined by measuring the reporter gene construct expression, e.g. in case GFP is used, green fluorescence intensity may be determined as a measure of the expression level of the RNA transcription factor.
  • compositions useful in the methods of the present disclosure include those suitable for various routes of administration, including, but not limited to, intravenous, subcutaneous, intradermal, subdermal, intranodal, intratumoral, intramuscular,
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient/therapeutic which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated and the particular mode of administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount (in weight) will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
  • gene means a DNA sequence comprising a region (transcribed region), which is transcribed into an RNA molecule (e.g. an mRNA) in a cell, operably linked to suitable regulatory regions (e.g. a promoter).
  • a gene may thus comprise several operably linked sequences, such as a promoter, a 5' leader sequence comprising e.g. sequences involved in translation initiation, a (protein) coding region (cDNA or genomic DNA) and a 3' non- translated sequence comprising e.g. transcription termination sites.
  • inhibits a neoplasia slows, decreases, or stabilizes the growth, proliferation, or metastasis of a neoplasia, or increases apoptosis.
  • “Mammal,” as used herein, refers to any member of the class Mammalia, including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like.
  • the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be included within the scope of this term.
  • Neoplasia any disease that is caused by or results in inappropriately high levels of cell division, inappropriately low levels of apoptosis, or both.
  • cancer is a neoplasia.
  • Neoplasia includes solid tumors and non-solid tumors or blood tumors.
  • cancers include, without limitation, leukemias, lymphoma .sarcomas and carcinomas (e.g.
  • colon cancer pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, lung cancer, melanoma, lymphoma, non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid cancer, papillary thyroid carcinoma, lung cancer, non-small cell lung carcinoma, and adenocarcinoma of lung).
  • a "nucleic acid” may include any polymer or oligomer of pyrimidine and purine bases, preferably cytosine, thymine, and uracil, and adenine and guanine, respectively (See Albert L. Lehninger, Principles of Biochemistry, at 793-800 (Worth Pub. 1982) which is herein incorporated by reference in its entirety for all purposes).
  • the present invention contemplates any deoxyribonucleotide, ribonucleotide or peptide nucleic acid component, and any chemical variants thereof, such as methylated, hydroxymethylated or glycosylated forms of these bases, and the like.
  • the polymers or oligomers may be heterogenous or homogenous in composition, and may be isolated from naturally occurring sources or may be artificially or synthetically produced.
  • the nucleic acids may be DNA or RNA, or a mixture thereof, and may exist permanently or transitionally in single-stranded or double-stranded form, including homoduplex, heteroduplex, and hybrid states.
  • “Pharmaceutically acceptable” is employed herein to refer to those combinations of a therapeutic as described herein, other drugs or therapeutics, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals, without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically-acceptable carrier”, as used herein, means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • protein or “polypeptide” are used interchangeably and refer to molecules consisting of a chain of amino acids, without reference to a specific mode of action, size, 3 dimensional structure or origin. A “fragment” or “portion” of a protein may thus still be referred to as a “protein”.
  • isolated protein is used to refer to a protein which is no longer in its natural environment, for example in vitro or in a recombinant bacterial or plant host cell.
  • RNA interference refers to a process of sequence-specific, post-transcriptional gene silencing (PTGS).
  • RNA interference is a system within living cells that takes part in controlling which genes are active and how active they are. RNAs are the direct products of genes, and these small RNAs can bind to other specific RNAs (mRNA) and decrease their activity, for example by preventing a messenger RNA from producing a protein.
  • RNA molecules capable of RNA interference include, without limitation, siRNA, shRNA, and miRNA.
  • small molecule is understood to refer to a chemical compound having a molecular weight below 2,500 daltons, more preferably between 300 and 1 ,500 daltons, and still more preferably between 400 and 1000 daltons. It is preferred that these small molecules are organic molecules. In certain embodiments, "small molecule” does not include peptide or nucleic acid molecules.
  • subject is intended to include vertebrates, preferably a mammal, including human and non-human mammals such as non-human primates. Human subjects are can be be referred to as patients.
  • a subject "suffering from or suspected of suffering from” a specific disease, condition, or syndrome has at least one risk factor and/or presents with at least one sign or symptom of the disease, condition, or syndrome such that a competent individual would diagnose or suspect that the subject was suffering from the disease, condition, or syndrome.
  • treat refers to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
  • Ranges provided herein are understood to be shorthand for all of the values within the range.
  • a range of 1 to 20 is understood to include any number, combination of numbers, or sub-range from the group including 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, or 20.
  • At least a particular value is understood to mean that value or more.
  • at least 2 is understood to be the same as “2 or more” i.e., 2, 3, 4, 5, 6, etc.
  • the disclosure relates to a method of treating or preventing a neoplasia in a subject, the method comprising administrating to a subject in need of such treatment an effective amount of a PDK inhibitor, preferably a PDK-1 inhibitor, and an effective amount of an inhibitor of a protein of the MAPK/ERK pathway.
  • a PDK inhibitor preferably a PDK-1 inhibitor
  • an effective amount of an inhibitor of a protein of the MAPK/ERK pathway preferably a PDK-1 inhibitor
  • a PDK inhibitor to the treatment of neoplasia with an inhibitor of (a protein of) the MAPK/ERK-pathway leads to further sensitization of the neoplastic cells, for example as reflected by decreased cell viability.
  • an inhibitor of (a protein of) the MAPK/ERK-pathway leads to further sensitization of the neoplastic cells, for example as reflected by decreased cell viability.
  • neoplastic cells that show resistance to the treatment by a
  • sensitization indicates an increased sensitivity of the cells towards a treatment. Sensitization can for example be reflected in cell viability. In case a particular treatment, in comparison to another treatment, leads to decreased cell viability (of the neoplastic cells), this is a clear indication of sensitization.
  • neoplastic cells for example tumors like melanoma
  • a protein of the MAPK/ERK pathway e.g. BRAF
  • the enzymatic activity of an enzyme can, for example be inhibited by allowing small molecules or antibodies or any other type of molecule to interact with the enzyme is such manner that the enzyme can not, or only to a limited amount, perform its undesired function, for example by binding close to or in a site in the protein normally used for ligand binding, or by using a compound that modifies the tertiary structure of the protein.
  • the inhibition may comprise modifying the target enzyme/protein such that it stuck (to a certain degree) in its "on" or "off” position (e.g. being or not being phosphorylated).
  • PDK also referred to as PDHK
  • PDK-1 PDK-1
  • PDK-2 PDK-2
  • PDK-3 PDK-3
  • PDK-4 Popov et al 1997 Adv. Second Messenger Phosphoprotein Res. 31 , 105-11 1 ; Kolobova et al 2001 Biochem. J. 358, 69-77; Korotchkina and Patel 2001 J. Biol. Chem.
  • Pyruvate dehydrogenase kinase (PDK) isoforms PDK1 , 2, 3, or 4 are molecular switches that downregulate the pyruvate dehydrogenase complex (PDC) by reversible phosphorylation in mitochondria.
  • the pyruvate dehydrogenase complex (PDC) is a member of the highly conserved
  • mitochondrial a-ketoacid dehydrogenase complexes comprising the PDC, the branched-chain a-ketoacid dehydrogenase complex (BCKDC), and the a-ketoglutarate dehydrogenase complex (Patel and Roche 1990 FASEB J. 4, 3224-3233; Reed 2001 J. Biol. Chem. 276,
  • PDC catalyzes the oxidative decarboxylation of pyruvate to give rise to acetyl- CoA, linking glycolysis to the Krebs cycle.
  • the phosphorylation of specific serine residues by PDK results in the inactivation of PDC, whereas the dephosphorylation by pyruvate dehydrogenase phosphatise (PDP) restores PDC activity (Harris et al 2001 Adv. Enzyme Regul. 41 , 269-288; Holness and Sugden 2003 Biochem. Soc. Trans. 31 , 1 143-1151).
  • PDK e.g. PDK-1
  • PDC pyruvate dehydrogenase complex
  • E2 dihydrolipoamide acetyltransferase E2
  • the reaction catalyzed by pyruvate dehydrogenase is considered to be the rate-limiting step for the pyruvate dehydrogenase complex.
  • a PDK polypeptide or peptide is to indicate a polypeptide having pyruvate dehydrogenase kinase activity and having at least 85% amino acid identity to the amino acid sequence of human PDK1 , PDK2 (e.g. Genbank Accession NO: AAH40478) , PDK3 (e.g. Genbank Accession NO: AAH15948), or PDK4 (e.g. Genbank Accession NO: NP002603).
  • These amino acid sequence of PDK enzymes, other proteins mentioned herein, and variations thereof are available in GenBAnk, accessible via http:/7www.ncbi.nlm.nih.gov/genbank / by entering either the numbers mentioned above or entering the relevant protein name.
  • PDK biological activity is meant any function of a pyruvate dehydrogenase kinase, such as enzymatic activity, kinase activity, inhibition of the tricarboxylic acid cycle, the enhancement of cell survival under hypoxic conditions, or inhibition of PDH activity.
  • PDK1 polypeptide is meant a polypeptide having substantial identity to the amino acid sequence provided at GenBank Accession No. NP-002601 , or an active fragment thereof.
  • PDK1 nucleic acid molecule is meant a nucleic acid sequence encoding a PDK1 polypeptide.
  • One exemplary nucleic acid sequence is provided at GenBank Accession No. NM-002610.
  • PDK1 biological activity is meant any function of PDK1 , such as enzymatic activity, kinase activity, inhibition of the tricarboxylic acid cycle, the enhancement of cell survival under hypoxic conditions, or the inhibition of PDH activity.
  • PDK inhibitor is meant a compound that reduces the biological activity of PDK1 , 2, 3, or 4; or that reduces the expression of an mRNA encoding a PDK polypeptide; or that reduces the expression of a PDK polypeptide, , for example by 5%, 10%, 15%, 20%, 25% or 50%, or even by as much as 75%, 85%, 95% or more in comparison to a control situation.
  • PDK1 polypeptide is meant a polypeptide having substantial identity to the amino acid sequence provided at GenBank Accession No. NP-002601 , or an active fragment thereof.
  • PDK1 nucleic acid molecule is meant a nucleic acid sequence encoding a PDK1 polypeptide.
  • One exemplary nucleic acid sequence is provided at GenBank Accession No. NM-002610.
  • PDK1 biological activity is meant any function of PDK1 , such as enzymatic activity, kinase activity, inhibition of the tricarboxylic acid cycle, the enhancement of cell survival under hypoxic conditions, or the inhibition of PDH activity.
  • PDK1 inhibitor is meant a compound that reduces the biological activity of PDK1 , that reduces the expression of an mRNA encoding a PDK1 polypeptide; or that reduces the expression of a PDK1 polypeptide, for example by 5%, 10%, 15%, 20%, 25% or 50%, or even by as much as 75%, 85%, 95% or more in comparison to a control situation.
  • Pyruvate dehydrogenase kinase inhibitors are known in the art and are described, for example, by Mann et al., Biochimica et Biophysica Acta 1480:283-292, 2000; Kato et al Structure. 2007 August; 15(8): 992-1004; Mayer Biochem Soc Trans. 2003 Dec;31 (Pt 6):1 165-7; WO2006042062, US2012004284 (for example in Table 1 thereof),
  • Known pyruvate dehydrogenase kinase inhibitors suitable in the current invention include dichloroacetate, halogenated acetophones (e.g., dichloroacetophenone) (Mann et al., supra), adenosine 5'[[beta],[gamma]-imido] triphosphate (Mann et al., supra), substituted triterpenes (Mann et al., supra), lactones (Mann et al., supra), monochloroacetate (Whitehouse et al., Biochem J 141 : 761-774, 1974), dichloroacetate (Whitehouse et al., supra), trichloroacetate (Whitehouse et
  • Suitable PDK-I inhibitors are those described in in particular W01999/062506 (preferred), W01999/44618, WO2009/067767 and US201 1/0207694. See for further details on AZD7545, and its synthesis for example W01999/062506, Mayers et al 2005 Biochem. Soc. Trans. 33, 367-370; Mayers et al 2005 Biochem. Soc. Trans. 33, 367-370.
  • PDK inhibitors include dichloroacetate, 2,2-dichloroacetophenone, and (+)-l-N-[2,5-(,S',JR)- dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R ) -3,3,3-triiluoro-2- hydroxy-2- methylpropanamide), see for example WO2006042062.
  • PDK1 inhibitor is AZD7545, (+)-1-N-[2,5-(S,R)-dimethyl-4-N-(4- cyanobenzoyl)piperazine]-(R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide (Aicher et al., supra)
  • AZD7545 is disclosed in W01999/062506 as one of many inhibitors having corresponding molecular structure.
  • the compounds are also suitable as PDK inhibitors for use in the current invention.
  • Other preferred PDK inhibitors are dichloroacetate and 2,2-dichloroacetophenone (see for example Kato et al supra).
  • a preferred PDK-1 inhibitor is AZD7545, and the term AZD7545 is to be construed as including modified versions of AZD7545 having PDK inhibitor activity.
  • AZ12 and Nov3r are PDK inhibitors known to be related to AZD7545 (Knoechel et al 2006
  • the PDK (or PDK-1) inhibitor is a small interfering nucleotide sequence capable of inhibiting PDK (or PDK-1) activity, such as siRNA using one or more small double stranded RNA molecules.
  • PDK activity in a cell can be decreased or knocked down by exposing (once or repeatedly) the cell to an effective amount of the appropriate small interfering nucleotide sequence.
  • the skilled person knows how to design such small interfering nucleotide sequence, for example as described in handbooks such as Doran and Helliwell RNA interference: methods for plants and animals Volume 10 CABI 2009.
  • the inhibitory nucleic acid molecule is a PDK1 siRNA, for example having the following sequence: 5'-CUACAUGAGUCGCAUUUCAdTdT-3.' (see US2009/0209618 for this and other examples).
  • the PDK (e.g. PDK-1) inhibitor according to the present invention may be a binding agent such as an antibody which specifically binds PDK (e.g. PDK-1), thereby inhibiting its function.
  • a binding agent such as an antibody which specifically binds PDK (e.g. PDK-1), thereby inhibiting its function.
  • Pyruvate dehydrogenase kinase catalytic activity may be assayed by measuring NADH formation by the pyruvate dehydrogenase multienzyme complex (PDC) (Mann et al., supra), by measuring PDH phosphorylation (see US2009209618), by measuring PDH activity (Aicher et al. J. Med. Chem. 43:236-249, 2000) or as described by Kato et al, Structure 15, 992-1004, 2007.
  • PDC pyruvate dehydrogenase multienzyme complex
  • the protein of the MAPK/ERK pathway is selected from the group consisting of BRAF, MEK and ERK, and combination of two or three thereof.
  • the protein is BRAF (B-raf).
  • a BRAF polypeptide or peptide is to indicate a polypeptide having serine/threonine protein kinase activity, e.g. BRAF kinase phosphorylates and activates MEK (MEK1 and MEK2, and having at least 85% amino acid identity to the amino acid sequence of human BRAF (e.g. Genbank Accession NO: NP004324).
  • BRAF kinase phosphorylates and activates MEK (MEK1 and MEK2, and having at least 85% amino acid identity to the amino acid sequence of human BRAF (e.g. Genbank Accession NO: NP004324).
  • GenBAnk accessible via http://www.ncbi.nlm.nih.gov/genbank by entering either the numbers mentioned above or entering the relevant protein name.
  • BRAF biological activity is meant any function of BRAF, such as enzymatic activity, kinase activity, or signaling the MAPK/ERK pathway.
  • BRAF inhibitor is meant a compound that reduces the biological activity of BRAF; or that reduces the expression of an mRNA encoding a BRAF polypeptide; or that reduces the expression of a BRAF polypeptide, for example by 5%, 10%, 15%, 20%, 25% or 50%, or even by as much as 75%, 85%, 95% or more in comparison to a control situation.
  • BRAF (or BRAF) is a member of the RAF family, which includes ARAF and CRAF in humans (Ikawa, Mol Cell Biol. 8(6):2651-4 (1988)).
  • BRAF is a serine/threonine protein kinase and participates in the RAS/RAF/MEK ERK mitogen activated protein kinase pathway (MAPK pathway, see Williams & Roberts, Cancer Metastasis Rev. 13(1): 105-16 (1994); Fecher et al 2008 Curr Opin Oncol 20, 183-189).
  • Any BRAF inhibitor including any pharmaceutical agent having BRAF inhibitory activity may be utilized in the present invention.
  • BRAF inhibitors are described, for instance, in WO 2010/114928, WO 2005/123696, WO2007/002325, WO 2006/003378, WO 2006/024834, WO 2006/024836, WO 2006/040568, WO 2006/067446 and WO 2006/079791 , WO02/24680 and WO03/022840, WO 2005/047542, AU 2003/286447, US 2004/0096855, AU2002/356323, WO2005089443, WO2006053201 , US20050267060, WO2008120004, US20090181371 ,
  • Preferred BRAF inhibitors include Vemurafenib, PLX4720 (Tsai et al. 2008 PNAS
  • dasatinib also known as BMS-354825, e.g. as produced by Bristol-Myers Squibb and sold under the trade name Sprycel
  • erlotinib e.g. as marketed by Genentech and OSI pharmaceuticals as Tarceva
  • gefitinib e.g. Iressa, AstraZeneca and Teva
  • imatinib e.g. as marketed by Novartis as Gleevex or Glivec
  • lapatinib e.g. from
  • Tykerb or Tyverb sorafenib (e.g. from Bayer and Onyx pharmaceuticals as Nexavar) and sunitinib (e.g. Sutent by Pfizer), or a derivative thereof.
  • the derivative of the BRAF inhibitor is a salt.
  • the BRAF inhibitor may be selected from the group consisting of dasatinib, erlotinib
  • the BRAF inhibitor is sorafenib tosylate.
  • Vemurafenib also known as PLX4032, RG7204 or R05185426, e.g. marketed as Zelboraf, from Plexxikon (Daiichi Sankyo group) and Hoffmann-La Roche.
  • the BRAF inhibitor is selected from any one of the BRAF inhibitors disclosed in WO2006/024834, W02006/067446, PCT/GB2006/004756, or is selected from any one of CHIR-265 (Novartis), XL281 (Exelixis) or PLX4032 (Plexxikon, or Roche). In one embodiment the BRAF inhibitor is selected from any one of the BRAF inhibitors disclosed in WO2008120004.
  • Braf inhibitors include GSK2118436, benzenesulfonamide, N-[3-[5- (2-amino-4-pyrimidinyl)-2-(1 , 1-dimethylethyl)-4-thiazolyl]- 2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1 : 1), N- ⁇ 3-[5-(2-aminopyrimidin-4-yl)-2-(1 , 1-dimethylethyl)thiazol-4-yl]-2- fluorophenyl ⁇ -2,6- difluorobenzenesulfonamide monomethanesulfonate (Clin Cancer Res. 201 1 ; doi: 10.1158/1078-0432; http://www.ama-assn.org/resources/doc/usan/dabrafenib.pdf).
  • the BRAF inhibitor is a small interfering nucleotide sequence capable of inhibiting BRAF activity, such as siRNA using one or more small double stranded RNA molecules.
  • BRAF activity in a cell can be decreased or knocked down by exposing (once or repeatedly) the cell to an effective amount of the appropriate small interfering nucleotide sequence.
  • the skilled person knows how to design such small interfering nucleotide sequence, for example as described in handbooks such as Doran and Helliwell RNA interference: methods for plants and animals Volume 10 CABI 2009.
  • a variety of techniques can be used to assess interference with BRAF activity of such small interfering nucleotide sequence, such as described in WO 2005/047542, for example by determining whether the candidate small interfering nucleotide sequence decreases BRAF activity.
  • Candidate small interfering nucleotide sequences that are capable of interference may be selected to further analysis to determine whether they also inhibit proliferation of melanoma cells, for example by assessing whether changes associated with inhibition of proliferation of melanoma cells occurs in melanoma cells.
  • the BRAF inhibitor according to the present invention may be a binding agent such as an antibody which specifically binds activated and/or mutated BRAF such as the ones described in WO 2005/047542, or as described in US 2004/0096855.
  • a BRAF inhibitor has BRAF inhibitor activity, or in other words reduces activated (or mutated) BRAF activity, which activity may be verified by the following assay. For example, using the procedure set out below of a BRAF in vitro ELISA assay.
  • Activity of human recombinant, purified wild type His-BRAF protein kinase can be determined in vitro using an enzyme-linked immunosorbent assay (ELISA) assay format, which measures phosphorylation of the BRAF substrate, human recombinant, purified 5 His-derived ELISA assay format, which measures phosphorylation of the BRAF substrate, human recombinant, purified 5 His-derived ELISA assay format, which measures phosphorylation of the BRAF substrate, human recombinant, purified 5 His-derived
  • the reaction utilizes 2.5 nM BRAF, 0.15 ⁇ MEK and 10 ⁇ adenosine triphosphate (ATP) in 40 mM N-(2-hydroxyethyl)piperazine-N'-(2- ethanesulfonic acid hemisodium salt (HEPES)3 5 mM 1 ,4-dithio-DL-threitol (DTT), 10 mM MgCI2, 1 mM ethylenediaminetetraacetic acid (EDTA) and 0.2 M NaCI (Ix HEPES buffer), with or without compound at various concentrations, in a total reaction volume of 25 ⁇ in 384 well plates.
  • HEPES N-(2-hydroxyethyl)piperazine-N'-(2- ethanesulfonic acid hemisodium salt
  • DTT mM 1 ,4-dithio-DL-threitol
  • EDTA ethylenediaminetetraacetic acid
  • BRAF and compound were preincubated in Ix HEPES buffer for 1 hour at 25 0C. Reactions are initiated with addition of MEK and ATP in Ix HEPES buffer and incubated at 25 °C for 50 minutes and reactions are stopped by addition of 10 ⁇ 1 175 mM EDTA (final concentration 50 mM) in Ix HEPES buffer. 5 ⁇ of the assay mix was then diluted 1 :20 into 50 mM EDTA in Ix HEPES buffer, transferred to 384 well black high protein binding plates and incubated overnight at 4 °C.
  • Plates were washed in tris buffered saline containing 0.1 % Tween20 (TBST), blocked with 50 ⁇ Superblock (Pierce) for 1 hour at 25 °C, washed in TBST, incubated with 50 ⁇ rabbit polyclonal anti-phospho-MEK antibody (Cell Signaling) diluted 1 :1000 in TBS for 2 hours at 25 °C, washed with TBST, incubated with 50 ⁇ goat anti-rabbit horseradish peroxidase -linked antibody (Cell Signaling) diluted 1 :2000 in TBS for 1 hour at 25 °C and washed with TBST.
  • TST tris buffered saline containing 0.1 % Tween20
  • a BRAF inhibitor according to the present invention will reduce BRAF activity by for example by 5%, 10%, 15%, 20%, 25% or 50%, or even by as much as 75%, 85%, 95% or more in comparison to the situation without BRAF inhibitor.
  • a MEK polypeptide (e.g. EC 2.7.12.2) or peptide is to indicate a polypeptide having serine/threonine protein kinase activity, e.g. MEK1 (e.g. Genbank Accession NO: NP002746) and MEK2 (e.g. Genbank Accession NO: NP109587) phosphorylates and activates MAPK, and having at least 85% amino acid identity to the amino acid sequence of human MEK1 , 2 or MEK3 ((e.g. Genbank Accession NO: NP002747).
  • MEK1 e.g. Genbank Accession NO: NP002746
  • MEK2 e.g. Genbank Accession NO: NP1095807
  • phosphorylates and activates MAPK and having at least 85% amino acid identity to the amino acid sequence of human MEK1 , 2 or MEK3 ((e.g. Genbank Accession NO: NP002747).
  • MEK biological activity is meant any function of MEK, such as enzymatic activity, kinase activity, or signaling the MAPK/ERK pathway.
  • MEK inhibitor is meant a compound that reduces the biological activity of MEK; or that reduces the expression of an mRNA encoding a MEK polypeptide; or that reduces the expression of a MEK polypeptide, for example by 5%, 10%, 15%, 20%, 25% or 50%, or even by as much as 75%, 85%, 95% or more in comparison to a control situation.
  • a MEK inhibitor can inhibit one member, several members or all members of the family of MEK kinases.
  • MEK inhibitors already known in the art, and suitable for use in the current invention, include but are not limited to the MEK inhibitors PD184352 and PD98059, inhibitors of MEKI and MEK2 U0126 (see Favata, M., et al., Identification of a novel inhibitor of mitogen- activated protein kinase. J. Biol. Chem. 273, 18623, 1998) and SL327 (Carr et al
  • MEK inhibitors are for example described in Tecle et al Medicinal Chemistry Letters Volume 19, Issue 1 , 1 January 2009, Pages 226-229; WO2009018238,
  • WO2007/044084 WO2005/051300, WO2011/095807, WO2008124085, WO2009018233, WO2007113505, US2011 105521 , WO2011067356, WO2011067348, US2010004247, and US2010130519.
  • GSK1120212 is an example of a further MEK inhibitor.
  • the MEK inhibitor may also preferably be selected from AZD6244, 4-(4-Bromo-2- fluorophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6-oxo- 1 ,6-dihydropyridazine-3- carboxamide or 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6- oxo-l,6- dihydropyridine-3-carboxamide.
  • the MEK inhibitor is selected from AZD6244 or a pharmaceutically acceptable salt thereof.
  • the MEK inhibitor is AZD6244 hydrogen sulphate salt.
  • AZD6244 hydrogen sulphate salt and derivates thereof may be synthesised according to the process described in WO2007/076245.
  • the MEK inhibitor is selected from 6-(4-Bromo-2-chloro- phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy- ethoxy)- amide or a pharmaceutically acceptable salt thereof.
  • the MEK inhibitor is 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5- carboxylic acid (2-hydroxy-ethoxy)-amide hydrogen sulphate salt.
  • 6-(4-Bromo-2-chloro- phenylamino)-7- fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy- ethoxy)-amide hydrogen sulphate salt may be synthesised according to the process described in International Patent Publication Number WO2007/076245.
  • the MEK inhibitor may be selected from the group consisting of certain experimental compounds, some of which are currently in Phase 1 or Phase II studies, namely PD-325901 (Phase 1 , Pfizer), XL518 (Phase 1 , Genentech), PD- 184352 (Allen and Meyer Semin Oncol. 2003 Oct;30(5 Suppl 16): 105-16.), PD- 318088 (Tecle et al nic & Medicinal Chemistry Letters Volume 19, Issue 1 , 1 January 2009, Pages 226-229), AZD6244 (Phase II, Dana Farber, AstraZeneca) and CI-1040 (Lorusso et al Journal of clinical oncology 2005, vol.
  • the MEK inhibitor is selected from any one of AZD6244 (Example 10 of WO03/077914) or a pharmaceutically acceptable salt thereof, 2-(2-fluoro-4- iodophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6-oxo- 1 JS- dihydropyridine-3- carboxamide or a pharmaceutically acceptable salt thereof, 4-(4-Bromo-2- fluorophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6-oxo- 1 ,6-dihydropyridazine-3- carboxamide or a pharmaceutically acceptable salt thereof, PD-0325901 (Pfizer), PD- 184352 (Pfizer), XL-518 (Exelixis), AR-1 19 (Ardea Biosciences, Valeant Pharmaceuticals), AS- 701 173 (Merck Ser
  • the MEK inhibitor is selected from AZD6244 or a pharmaceutically acceptable salt thereof, 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6-oxo- 1 JS- dihydropyridine-3-carboxamide or a pharmaceutically acceptable salt thereof or 4-(4-Bromo- 2-fluorophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6-oxo- 1 ,6-dihydropyridazine-3- carboxamide or a pharmaceutically acceptable salt thereof as described below.
  • the MEK inhibitor is selected from AZD6244 or a pharmaceutically acceptable salt thereof or 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6-oxo- 1 JS- dihydropyridine-3-carboxamide or a pharmaceutically acceptable salt thereof, as described below.
  • the MEK inhibitor is AZD6244 hydrogen sulphate salt.
  • AZD6244 hydrogen sulphate salt may be synthesised according to the process described in WO07/076245.
  • the MEK inhibitor may inhibit (gene) expression of MEK, for example by interfering with mRNA stability or translation.
  • the MEK inhibitor is selected from small interfering RNA (siRNA), which is sometimes known as short interfering RNA or silencing RNA, or short hairpin RNA (shRNA), which is sometimes known as small hairpin RNA.
  • siRNA small interfering RNA
  • shRNA short hairpin RNA
  • the MEK inhibitor according to the present invention may be a binding agent such as an antibody which specifically binds MEK, thereby inhibiting its function.
  • a number of assays for identifying kinase inhibitors are known.
  • Davies et al (2000) describe kinase assays in which a kinase is incubated in the presence of a peptide substrate and radiolabeled ATP. Phosphorylation of the substrate by the kinase results in incorporation of the label into the substrate. Aliquots of each reaction are immobilised on phosphocellulose paper and washed in phosphoric acid to remove free ATP. The activity of the substrate following incubation is then measured and provides an indication of kinase activity. The relative kinase activity in the presence and absence of candidate kinase inhibitors can be readily determined using such an assay.
  • a ERK polypeptide or peptide is to indicate a polypeptide having serine/threonine protein kinase activity, e.g. ERK phosphorylates and activates MAP (microtubule-associated proteins), and having at least 85% amino acid identity to the amino acid sequence of a human ERK, e.g to ERK1 (e.g. Genbank Accession NO: NP001035145) or ERK2 (e.g. Genbank Accession NO: NP002736) .
  • ERK1 e.g. Genbank Accession NO: NP001035145
  • ERK2 e.g. Genbank Accession NO: NP002736
  • ERK biological activity is meant any function of ERK, such as enzymatic activity, kinase activity, the ability to phosphorylate an ERK substrate, or signaling the MAPK/ERK pathway.
  • ERK inhibitor is meant a compound that reduces the biological activity of ERK; or that reduces the expression of an mRNA encoding a ERK polypeptide; or that reduces the expression of an ERK polypeptide, for example by 5%, 10%, 15%, 20%, 25% or 50%, or even by as much as 75%, 85%, 95% or more in comparison to a control situation.
  • An ERK inhibitor can inhibit one member, several members or all members of the family of ERK kinases .
  • ERK extracellularly regulated kinase
  • MAP kinases which regulate the growth and proliferation of cells
  • Embodiments of the invention include an ERK inhibitor that inhibits or reduces ERK protein expression, amount of ERK protein or level of ERK translation, amount of ERK transcript or level of ERK transcription, stability of ERK protein or ERK transcript, half-life of ERK protein or ERK transcript, prevents the proper localization of an ERK protein or transcript; reduces or inhibits the availability of ERK polypeptide, reduces or inhibits ERK activity; reduces or inhibits ERK, binds ERK protein, or inhibits or reduces the post-translational modification of ERK, including its phosphorylation.
  • the above described inhibitory action are also to be construed to apply, in comparable fashion to any inhibitor described herein for its specific target (e.g. a BRAF inhibitor for BRAF).
  • the ERK inhibitor is an ERK inhibitor such as disclosed in WO2002058687, for example SL-327 (Carr et al Psychopharmacology (Berl). 2009 Jan;201 (4):495-506), U0126 (Favata, M., et al., Identification of a novel inhibitor of mitogen-activated protein kinase. J. Biol. Chem. 273, 18623, 1998), PD098059 (Alessi et al J Biol Chem. 1995 Nov 17;270(46):27489-94), or PD184352 (Allen and Meyer Semin Oncol. 2003 Oct;30(5 Suppl 16): 105-16).
  • the ERK inhibitor is U0126.
  • the ERK inhibitor is U0126 or a pharmaceutically acceptable salt or solvate thereof, or an analogue thereof, wherein the analogue has ERK inhibitory activity.
  • the inhibitor may be PD98059 or an analogue thereof, wherein the analogue has ERK inhibitory activity.
  • the ERK inhibitor is PD0325901 (Henderson et al Mol Cancer Ther July 2010 9; 1968). Further suitable ERK inhibitors may be found in patentdocuments WO2002058687,
  • ERK inhibitors include 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059), 1 ,4-diamino-2,3-dicyano-1 ,4-bis(2-aminophenylthio)butadiene (U0126), and Z-& E-a-(amino-((4-aminophenyl)thio)methylene)-2-(trifluoromethyl)benzeneacetonitrile (MEK1/2) (US201 11 10916).
  • PD98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • U0126 1 ,4-diamino-2,3-dicyano-1 ,4-bis(2-aminophenylthio)butadiene
  • MEK1/2 Z-& E-a-(amino-((4-aminophenyl)thio)methylene)-2
  • the ERK inhibitor is a small interfering nucleotide sequence capable of inhibiting ERK activity, such as siRNA using one or more small double stranded RNA molecules.
  • ERK activity in a cell can be decreased or knocked down by exposing (once or repeatedly) the cell to an effective amount of the appropriate small interfering nucleotide sequence.
  • the skilled person knows how to design such small interfering nucleotide sequence, for example as described in handbooks such as Doran and Helliwell RNA interference: methods for plants and animals Volume 10 CABI 2009.
  • Candidate small interfering nucleotide sequences that are capable of interference may be selected to further analysis to determine whether they also inhibit proliferation of melanoma cells, for example by assessing whether changes associated with inhibition of proliferation of melanoma cells occurs in melanoma cells.
  • analogues, derivatives or modified versions of the above- documented ERK inhibitors may be used in the context of the present invention, as long as such analogues, derivatives or modified versions have ERK inhibitor activity.
  • the ERK inhibitor according to the present invention may be a binding agent such as an antibody which specifically binds ERK, thereby inhibiting its function.
  • ERK inhibitor activity may be assayed in vitro, in vivo or in a cell line.
  • In vitro assays include assays that determine inhibition of either the kinase activity or ATPase activity of activated ERK. Alternate in vitro assays quantitate the ability of the inhibitor to bind to ERK and may be measured either by radiolabelling the inhibitor prior to binding, isolating the inhibitor/ERK complex and determining the amount of radiolabel bound, or by running a competition experiment where new inhibitors are incubated with ERK bound to known radioligands. One may use any type or isoform of ERK, depending upon which ERK type or isoform is to be inhibited.
  • MAPK/ERK pathway in particular of ERK, BRAF and/or MEK, leads to better treatment response due to further sensitization of the neoplastic cells.
  • BRAF inhibitor in
  • the PDK inhibitor in AZD7545.
  • the PDK inhibitor is selected from the group consisting of dichloroacetate, halogenated acetophones (e.g., dichloroacetophenone), adenosine 5'[[beta],[gamma]-imido] triphosphate, substituted triterpenes, lactones, monochloroacetate, dichloroacetate, trichloroacetate, difluoroacetate, chlorofluoroacetic acid, 2-chloropropionate, 2,2'- dichloropropionate, chloropropionate, 3-chloropropionate, 3,3,3-trifluoro-2-hydroxy-2- methylpropionamide , SDZ048-619 (Novartis), SDZ060-01 1 (Novartis), and SDZ225-066 (Novar
  • W01999/062506 a PDK-I inhibitors disclosed in W01999/44618, a PDK-I inhibitors disclosed in WO2009/067767, a PDK-I inhibitors disclosed in US2011/0207694, dichloroacetate, 2,2- dichloroacetophenone, and (+)-l-N-[2,5-(,S',JR)-dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R ) -3,3,3-triiluoro-2- hydroxy-2-methylpropanamide), a PDK-I inhibitors disclosed in
  • WO2006042062 preferably a PDK-I inhibitors disclosed in W01999/062506, even more preferably AZD7545 and derivates thereof as disclosed in W01999/062506, ((2R)-N- ⁇ 4-[4- (dimethylcarbamoyl)phenylsulfonyl]-2-chlorophenyl ⁇ -3,3,3-trifluoro-2-hydroxy-2- methylpropanamide), or (+)-1-N-[2,5-(S,R)-dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R)- 3,3,3-trifluoro-2-hydroxy-2-methylpropanamide.
  • a BRAF inhibitor as disclosed in WO 2010/114928 selected from the group consisting of A BRAF inhibitor as disclosed in WO 2010/114928, A BRAF inhibitor as disclosed in WO 2005/123696, A BRAF inhibitor as disclosed in WO2007/002325, A BRAF inhibitor as disclosed in WO 2006/003378, A BRAF inhibitor as disclosed in WO 2006/024834, A BRAF inhibitor as disclosed in WO
  • a MEK inhibitor selected from the group consisting of PD184352, PD98059, U0126 , SL327, PDI 84352, a MEK inhibitor disclosed in WO2009018238, a MEK inhibitor disclosed in WO2007/044084, a MEK inhibitor disclosed in WO2005/051300, a MEK inhibitor disclosed in WO2011/095807, a MEK inhibitor disclosed in WO2008124085, a MEK inhibitor disclosed in WO2009018233, a MEK inhibitor disclosed in WO2007113505, a MEK inhibitor as disclosed in WO03/077914, a MEK inhibitor disclosed in US201 1105521 , a MEK inhibitor disclosed in WO2011067356, a MEK inhibitor disclosed in WO201 1067348, a MEK inhibitor disclosed in US2010004247, a MEK inhibitor disclosed in US2010130519, AEZS-131 .AZD6244, 4-(4- Bromo-2- fluorophenylamino)
  • -a ERK inhibitor selected from the group consisting of an ERK-inhibitor as disclosed in WO2002058687, SL-327, U0126, PD098059, PD184352, PD0325901 , an ERK-inhibitor as disclosed in WO2002058687, an ERK-inhibitor as disclosed in AU2002248381 , an ERK- inhibitor as disclosed in US20050159385, an ERK-inhibitor as disclosed in US2004102506, an ERK-inhibitor as disclosed in US2005090536, an ERK-inhibitor as disclosed in
  • HK11 17159 an ERK-inhibitor as disclosed in WO2009026487, an ERK-inhibitor as disclosed in WO2008115890, PH-797804 (Bioorg Med Chem Lett 201 1 Jul 1 ;21 (13):4066-71) an ERK- inhibitor as disclosed in US2009186379, an ERK-inhibitor as disclosed in WO2008055236, an ERK-inhibitor as disclosed in US2007232610, an ERK-inhibitor as disclosed in
  • WO2007025090 an ERK-inhibitor as disclosed in US2007049591 , 2-(2-amino-3- methoxyphenyl)-4H-1-benzopyran-4-one (PD98059), 1 ,4-diamino-2,3-dicyano-1 ,4-bis(2- aminophenylthio)butadiene (U0126), and Z-& E-a-(amino-((4-aminophenyl)thio)methylene)-2- (trifluoromethyl)benzeneacetonitrile (MEK1/2) (US2011 110916),
  • the neoplasia is a malignant neoplasia, preferably a malignant neoplasia that involves a disturbance in the MAPK/ERK pathway, preferably a malignant neoplasia selected from the group consisting of lymphoma, non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid cancer, papillary thyroid carcinoma, lung cancer, non-small cell lung carcinoma, and adenocarcinoma of lung.
  • a malignant neoplasia selected from the group consisting of lymphoma, non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid cancer, papillary thyroid carcinoma, lung cancer, non-small cell lung carcinoma, and adenocarcinoma of lung.
  • the malignant neoplasia is a melanoma, including BRAF V600K or BRAF V600R melanoma, preferably a BRAF (V600E) melanoma, and other BRAF(V600E) tumors, or tumors with alternative activation of the BRAF/MEK/ERK pathway.
  • the PDK inhibitor is an inhibitory nucleic acid molecule that reduces PDK gene and/or protein expression, preferably PDK-1 expression.
  • the inhibitory nucleic acid molecule is a small interfering RNA (siRNA, antisense RNA, short hairpin RNA or another nucleic acid inhibitor of PDK expression (e.g. (e.g., PDK1 , 2, 3, 4).
  • inhibitory nucleic acid molecule is meant a double-stranded RNA, antisense RNA, or siRNA, or portion thereof that reduces the amount of mRNA or protein encoded by a gene of interest. Preferably, the reduction is by at least 5%, more desirable by at least 10%, 25%, or even 50%, relative to an untreated control. Methods for measuring both mRNA and protein levels are well-known in the art.
  • the siRNA may contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or other modified backbones known in the art, or may contain non-natural internucleoside linkages.
  • the inhibitor of a protein of the MAPK/ERK pathway is an inhibitory nucleic acid molecule that reduces expression of BRAF, MEK or ERK.
  • the inhibitory nucleic acid molecule is a small interfering RNA (siRNA, antisense RNA, short hairpin RNA or another nucleic acid inhibitor of expression of a BRAF, MEK or ERK protein/gene, as exemplified above.
  • the inhibitor of a protein of the MAPK/ERK pathway decreases expression of a BRAF, MEK or ERK polypeptide, decreases the biological activity of a BRAF, MEK or ERK polypeptide, and/or decreases the expression of a BRAF, MEK or ERK nucleic acid molecule.
  • an effective amount of a PDK inhibitor preferably a PDK-1 inhibitor, and an effective amount of an inhibitor of a protein of the MAPK ERK pathway for use in treatment or prevention of a neoplasia in a subject.
  • a PDK inhibitor preferably a PDK-1 inhibitor
  • an effective amount of an inhibitor of a protein of the MAPK/ERK pathway for the manufacture of a medicament for treatment or prevention of a neoplasia in a subject.
  • the effective amount of a PDK inhibitor and the effective amount of a protein of the MAPK/ERK pathway or use thereof according to the invention wherein the subject is a subject that acquired resistance against treatment with a BRAF, MEK or ERK inhibitor.
  • a PDK inhibitor in another embodiment there is provided for the effective amount of a PDK inhibitor and the effective amount of a protein of the MAPK/ERK pathway or use thereof according to the invention wherein the PDK inhibitor is selected from the group consisting of dichloroacetate, halogenated acetophones (e.g., dichloroacetophenone), adenosine 5'[[beta],[gamma]-imido] triphosphate, substituted triterpenes, lactones, monochloroacetate, dichloroacetate, trichloroacetate, difluoroacetate, chlorofluoroacetic acid, 2-chloropropionate, 2,2'- dichloropropionate, chloropropionate, 3-chloropropionate, 3,3,3-trifluoro-2-hydroxy-2- methylpropionamide , SDZ048-619 (Novartis), SDZ060-01 1 (Novartis), and SDZ225-066 (Novart
  • W01999/062506 a PDK-I inhibitors disclosed in W01999/44618, a PDK-I inhibitors disclosed in WO2009/067767, a PDK-I inhibitors disclosed in US201 1/0207694, dichloroacetate, 2,2- dichloroacetophenone, and (+)-l-N-[2,5-(,S',JR)-dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R ) -3,3,3-triiluoro-2- hydroxy-2-methylpropanamide), a PDK-I inhibitors disclosed in
  • WO2006042062 preferably a PDK-I inhibitors disclosed in W01999/062506, even more preferably AZD7545 and derivates thereof as disclosed in W01999/062506, ((2R)-N- ⁇ 4-[4- (dimethylcarbamoyl)phenylsulfonyl]-2-chlorophenyl ⁇ -3,3,3-trifluoro-2-hydroxy-2- methylpropanamide), or (+)-1-N-[2,5-(S,R)-dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R)- 3,3,3-trifluoro-2-hydroxy-2-methylpropanamide.
  • the effective amount of a PDK inhibitor and the effective amount of a protein of the MAPK ERK pathway or use thereof according to the invention wherein the inhibitor of a protein of the MAPK/ERK pathway is selected from -a BRAF inhibitor selected from the group consisting of A BRAF inhibitor as disclosed in WO 2010/114928, A BRAF inhibitor as disclosed in WO 2005/123696, A BRAF inhibitor as disclosed in WO2007/002325, A BRAF inhibitor as disclosed in WO 2006/003378, A BRAF inhibitor as disclosed in WO 2006/024834, A BRAF inhibitor as disclosed in WO
  • a BRAF inhibitor as disclosed in WO 2006/040568 A BRAF inhibitor as disclosed in WO 2006/067446 or A BRAF inhibitor as disclosed in WO 2006/079791 , A BRAF inhibitor as disclosed in WO02/24680, or A BRAF inhibitor as disclosed in WO03/022840, A BRAF inhibitor as disclosed in WO 2005/047542, A BRAF inhibitor as disclosed in AU
  • a BRAF inhibitor as disclosed in US 2004/0096855 A BRAF inhibitor as disclosed in AU2002/356323, A BRAF inhibitor as disclosed in WO2005089443, A BRAF inhibitor as disclosed in WO2006053201 , A BRAF inhibitor as disclosed in US20050267060, A BRAF inhibitor as disclosed in WO2008120004, A BRAF inhibitor as disclosed in
  • -a MEK inhibitor selected from the group consisting of PD184352, PD98059, U0126 , SL327, PDI 84352, a MEK inhibitor disclosed in WO2009018238, a MEK inhibitor disclosed in
  • WO2007/044084 a MEK inhibitor disclosed in WO2005/051300, a MEK inhibitor disclosed in WO2011/095807, a MEK inhibitor disclosed in WO2008124085, a MEK inhibitor disclosed in WO2009018233, a MEK inhibitor disclosed in WO2007113505, a MEK inhibitor as disclosed in WO03/077914, a MEK inhibitor disclosed in US201 1105521 , a MEK inhibitor disclosed in WO2011067356, a MEK inhibitor disclosed in WO2011067348, a MEK inhibitor disclosed in US2010004247, a MEK inhibitor disclosed in US2010130519, AZD6244, 4-(4-Bromo-2- fluorophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6-oxo- 1 ,6-dihydropyridazine-3- carboxamide or 2-(2-fluoro-4-iodophenylamino)-N-(2-
  • -an ERK inhibitor selected from the group consisting of an ERK-inhibitor as disclosed in WO2002058687, SL-327, U0126, PD098059, PD184352, PD0325901 , an ERK-inhibitor as disclosed in WO2002058687, an ERK-inhibitor as disclosed in AU2002248381 , an ERK- inhibitor as disclosed in US20050159385, an ERK-inhibitor as disclosed in US2004102506, an ERK-inhibitor as disclosed in US2005090536, an ERK-inhibitor as disclosed in
  • HK11 17159 an ERK-inhibitor as disclosed in WO2009026487, an ERK-inhibitor as disclosed in WO2008115890, PH-797804 (Bioorg Med Chem Lett 201 1 Jul 1 ;21 (13):4066-71) an ERK- inhibitor as disclosed in US2009186379, an ERK-inhibitor as disclosed in WO2008055236, an ERK-inhibitor as disclosed in US2007232610, an ERK-inhibitor as disclosed in
  • WO2007025090 an ERK-inhibitor as disclosed in US2007049591 , 2-(2-amino-3- methoxyphenyl)-4H-1-benzopyran-4-one (PD98059), 1 ,4-diamino-2,3-dicyano-1 ,4-bis(2- aminophenylthio)butadiene (U0126), and Z-& E-a-(amino-((4-aminophenyl)thio)methylene)-2- (trifluoromethyl)benzeneacetonitrile (MEK1/2) (US2011 110916),
  • the neoplasia is a malignant neoplasia, preferably selected from the group consisting of a malignant neoplasia that involves a disturbance in the MAPK/ERK pathway, a malignant neoplasia selected from the group consisting of lymphoma, non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid cancer, papillary thyroid carcinoma, lung cancer, non-small cell lung carcinoma, and adenocarcinoma of lung, preferably melanoma, more preferably BRAF (V600E) melanoma and other BRAF(V600E) tumors, or tumors with alternative activation of the BRAF/MEK/ERK pathway
  • the effective amount of a PDK inhibitor and the effective amount of a protein of the MAPK/ERK pathway or use thereof according to the invention wherein the PDK inhibitor decreases expression of a PDK polypeptide, decreases the biological activity of a PDK polypeptide, and/or decreases the expression of a PDK nucleic acid molecule.
  • the effective amount of a PDK inhibitor and the effective amount of a protein of the MAPK/ERK pathway or use thereof wherein the inhibitor of a protein of the MAPK/ERK pathway expression of a BRAF, MEK or ERK polypeptide, decreases the biological activity of a BRAF, MEK or ERK polypeptide, and/or decreases the expression of a BRAF, MEK or ERK nucleic acid molecule.
  • a pharmaceutical composition comprising an effective amount of a PDK inhibitor, preferably a PDK-1 inhibitor, and an effective amount of an inhibitor of a protein of the MAPK/ERK pathway, preferably BRAF, as defined or disclosed herein.
  • the current invention may be summarized, non-limiting,, as follows
  • a PDK inhibitor preferably a PDK-1 inhibitor, and an inhibitor of a protein of the
  • MAPK/ERK pathway for use in treatment or prevention of a neoplasia in a subject.
  • a PDK inhibitor preferably a PDK-1 inhibitor, and an inhibitor of a protein of the MAPK/ERK pathway for the manufacture of a medicament for treatment or prevention of a neoplasia in a subject.
  • a malignant neoplasia selected from the group consisting of lymphoma, non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid cancer, papillary thyroid carcinoma, lung cancer, non- small cell lung carcinoma, and adenocarcinoma of lung, preferably melanoma, BRAF V600K melanoma or BRAF V600R melanoma, more preferably BRAF (V600E) melanoma and other BRAF(V600E) tumors, or tumors with alternative activation of the BRAF/MEK/ERK pathway.
  • a malignant neoplasia selected from the group consisting of lymphoma, non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid cancer, papillary thyroid carcinoma, lung cancer, non- small cell lung carcinoma, and adenocarcinoma of lung, preferably melanoma, BRAF V600K melanoma
  • the inhibitor of a protein of the MAPK/ERK pathway is an inhibitory nucleic acid molecule that reduces expression of BRAF, MEK or ERK.
  • the PDK inhibitor is selected from the group consisting of dichloroacetate, halogenated acetophones (e.g., dichloroacetophenone), adenosine 5'[[beta],[gamma]-imido] triphosphate, substituted triterpenes, lactones, monochloroacetate, dichloroacetate, trichloroacetate, difluoroacetate,
  • acetyltransferase a PDK-I inhibitors disclosed in W01999/062506, a PDK-I inhibitors disclosed in W01999/44618, a PDK-I inhibitors disclosed in WO2009/067767, a PDK- I inhibitors disclosed in US201 1/0207694, dichloroacetate, 2,2-dichloroacetophenone, and (+)-l-N-[2,5-(,S',JR)-dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R ) -3,3,3-triiluoro- 2- hydroxy-2-methylpropanamide), a PDK-I inhibitors disclosed in WO2006042062, preferably a PDK-I inhibitors disclosed in W01999/062506, even more preferably AZD7545 and derivates thereof as disclosed in W01999/062506, ((2R)-N- ⁇ 4-[4- (dimethylcarbamoy
  • -a BRAF inhibitor selected from the group consisting of A BRAF inhibitor as disclosed in WO 2010/114928, A BRAF inhibitor as disclosed in WO 2005/123696, A BRAF inhibitor as disclosed in WO2007/002325, A BRAF inhibitor as disclosed in WO
  • a BRAF inhibitor as disclosed in WO 2006/024834 A BRAF inhibitor as disclosed in WO 2006/024836, A BRAF inhibitor as disclosed in WO 2006/040568, A BRAF inhibitor as disclosed in WO 2006/067446 or A BRAF inhibitor as disclosed in WO 2006/079791 , A BRAF inhibitor as disclosed in WO02/24680, or A BRAF inhibitor as disclosed in WO03/022840, A BRAF inhibitor as disclosed in WO 2005/047542, A
  • BRAF inhibitor as disclosed in WO2006/024834, A BRAF inhibitor as disclosed in WO2006/067446, A BRAF inhibitor as disclosed in PCT/GB2006/004756, CHIR-265, XL281 (Exelixis) or PLX4032, -a MEK inhibitor selected from the group consisting of PD184352, PD98059, U0126 ,
  • a MEK inhibitor disclosed in WO2009018238 a MEK inhibitor disclosed in WO2007/044084, a MEK inhibitor disclosed in WO2005/051300, a MEK inhibitor disclosed in WO201 1/095807, a MEK inhibitor disclosed in WO2008124085, a MEK inhibitor disclosed in WO2009018233, a MEK inhibitor disclosed in
  • WO2007113505 a MEK inhibitor as disclosed in WO03/077914, a MEK inhibitor disclosed in US2011 105521 , a MEK inhibitor disclosed in WO2011067356, a MEK inhibitor disclosed in WO201 1067348, a MEK inhibitor disclosed in US2010004247, a MEK inhibitor disclosed in US2010130519, AZD6244, 4-(4-Bromo-2- fluorophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-6-oxo- 1 ,6-dihydropyridazine- 3- carboxamide or 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)- 1 ,5-dimethyl-
  • 6- oxo-l,6-dihydropyridine-3-carboxamid 6-(4-Bromo-2-chloro- phenylamino)-7-fluoro- 3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy- ethoxy)-amide or a pharmaceutically acceptable salt thereof, 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro- 3-methyl-3H-benzoimidazole-5- carboxylic acid (2-hydroxy-ethoxy)-amide hydrogen sulphate salt, PD-325901 , XL518, PD-184352, PD- 318088, AZD6244, CI-1040, 4-(4-
  • -an ERK inhibitor selected from the group consisting of an ERK-inhibitor as disclosed in WO2002058687, SL-327, U0126, PD098059, PD184352, PD0325901 , an ERK- inhibitor as disclosed in WO2002058687, an ERK-inhibitor as disclosed in
  • an ERK-inhibitor as disclosed in US20050159385 an ERK-inhibitor as disclosed in US2004102506, an ERK-inhibitor as disclosed in US2005090536, an ERK-inhibitor as disclosed in US2004048861 , an ERK-inhibitor as disclosed in US20100004234, an ERK-inhibitor as disclosed in HR201 10892, an ERK-inhibitor as disclosed in WO201 1163330, an ERK-inhibitor as disclosed in TW200934775, an ERK-inhibitor as disclosed in EP2332922, an ERK-inhibitor as disclosed in
  • WO2011041152 an ERK-inhibitor as disclosed in US201 1038876, an ERK-inhibitor as disclosed in WO2009146034, an ERK-inhibitor as disclosed in HK11 17159, an ERK-inhibitor as disclosed in WO2009026487, an ERK-inhibitor as disclosed in WO2008115890, PH-797804 (Bioorg Med Chem Lett 201 1 Jul 1 ;21 (13):4066-71) an ERK-inhibitor as disclosed in US2009186379, an ERK-inhibitor as disclosed in WO2008055236, an ERK-inhibitor as disclosed in US2007232610, an ERK-inhibitor as disclosed in WO2007025090, an ERK-inhibitor as disclosed in US2007049591 , 2- (2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059), 1
  • Cells undergoing OIS (upon transduction of BRAF E600 ) or bypassing OIS (shC/EBP depletion in combination with BRAF E600 ), cycling and C/EBP depleted cells were fixed and stained 1 1 days after exposure to BRAF E600 .
  • D Schematic representation of major biochemical pathways in mammalian cells.
  • PDH a key enzyme linking glycolysis to oxidative phosphorylation is regulated through a reversible phosphorylation cycle.
  • Phosphorylation of PDH by PDK1 inhibits its action and pushes metabolism into glycolysis while
  • Hsp90 serves as loading control.
  • E PDH activity of the samples described in A measured by DipStick assay.
  • F-H Regulation of IL8 (F), IL6 (G) and C/EBPa (H) transcripts of the samples described in A as determined by qRT-PCR. Measurements are based on at least three independent experiments and standardized to the BRAF E600 - expressing senescent cells.
  • Figure 2 Suppl. PDK1 overexpression abrogates BRAF E600 -induced senescence independently of p16 INK4A status.
  • BRAF E600 Cells were fixed and stained 1 1 days after exposure to BRAF E600 .
  • BRAF E600 acts on PDH via downregulation of pyruvate dehydrogenase kinase isoform 1 (PDK1 or PDHK1) and upregulation of pyruvate dehydrogenase phosphatase (PDP2).
  • PDK1 or PDHK1 pyruvate dehydrogenase kinase isoform 1
  • PDP2 pyruvate dehydrogenase phosphatase
  • the human diploid fibroblast (HDF) cell line Tig3 expressing the ectopic receptor and hTERT (Tig3 (et)) and all melanoma cell lines were maintained in DMEM with 4.5 mg ml -1 glucose and 0.11 mg ml -1 sodium pyruvate, supplemented with 9% fetal bovine serum (PAA), 2 mM glutamine, 100 units ml -1 penicillin and 0.1 mg ml -1 streptomycin (GIBCO).
  • PAA fetal bovine serum
  • GABCO fetal bovine serum
  • Melanocytes were propagated in 254CF medium in the presence of 0.2 mM CaCI 2 and melanocyte growth supplement (Cascade Biologicals).
  • PDK1 was depleted with short hairpin (sh) RNAs encoded by lentiviral infections. Infections were performed using HEK293T cells as producers of viral supernatants. For infections, filtered (pore size 0.45 mm) viral supernatant, supplemented with 4-8 g ml "1 polybrene was used. In general, a single infection round of 6 h was sufficient to infect at least 90% of the population.
  • sh short hairpin
  • Cells were infected with shRNAs targeting PDK1 and selected pharmacologically (puromycin). After 5 days of selection, cells were seeded for cell viability assay in 24 well plates and for BrdU incorporation assays or trypan blue exclusion assay into six-well plates and maintained in the selection medium. For cell viability fixation and staining with crystal violet was performed 7 days after infection. Images of cell viability assays reflect representative results of several independent experiments. BrdU labelling was carried out for 3 h followed by fixation. Incorporated BrdU was detected by immunostaining as described in (Serrano et al., 1997) and FACS analysis. Results are represented as mean with SD of three or more independent experiments. Trypan blue exclusion assay was performed 6 days after infection as described previously (Forcet et al, 2001). Results are represented as the mean of at least three independent experiment +/- SD.
  • Lentiviral knockdown constructs were purchased from Sigma-Aldrich:
  • PDK1 5'- CCAAGACCTCGTGTTGAGACC-3' and 5'- AATACAGCTTCAGGTCTCCTTGG-3'; RPL13 was used as control.
  • the ⁇ method was applied. Data are represented as mean + s.d. of three or more independent experiments.
  • Antibodies used for immunoblotting were ⁇ -actin (AC-74; A5316; Sigma), PDHEI a ((9H9AF5); 459400; Invitrogen), phospho-PDHEIa [Ser293] (NB110-93479; Novus Biologicals), PDK1 (KAP-PK1 12; Stressgene)//pct
  • PDH activity was measured using the DipStick assay kit from MitoSciences (MSP90). Cells were lysed in the 10x sample buffer provided by the manufacturer, followed by centrifugation and measurement of the protein concentration with the BioRad Protein Assay. 140 mg of protein lysate was loaded and PDH activity was measured according to the manufacturer's protocol.
  • PDH is the key enzyme linking glycolysis to oxidative phosphorylation and it is regulated through a reversible phosphorylation cycle (Figure 1 D).
  • Phosphorylation of PDH by pyruvate dehydrogenase kinases (PDK1-4) inhibits its action and pushes metabolism into glycolysis, while dephosphorylation of PDH by pyruvate dehydrogenase phosphatases (PDP1&2) has the opposite effect.
  • PDH phosphorylation was reduced in cells undergoing BRAF E600 - induced senescence when compared to cycling cells and phosphorylation was restored when senescence was abrogated by C/EBP beta depletion (Figure 1C).
  • OIS abrogation upon PDK1 overexpression was associated with a marked reduction in (SA)- beta-galactosidase activity (Figure 2C) and p15 INK4B protein level (Figure 2D).
  • IL6 and IL8 transcript levels were significantly reduced in these cells when compared to OIS cells ( Figure 2 F&G) indicating a link between PDK1 and the senescence-messaging secretome (SMS).
  • SMS senescence-messaging secretome
  • induction of the C/EBPbeta transcript in the presence of BRAF E600 was also reduced upon PDK1 overexpression (Figure 2H), which together with upregulation of PDK1 upon C/EBPbeta silencing (Figure 1 C) suggests the existence of a feedback loop between these two.
  • PDK1 depletion is sufficient to induce senescence in primary cells
  • PDK.1 Depletion of PDK.1 induces cell death in BRAF mutant melanoma cell lines but not in primary cells.
  • a PDK1 inhibitor may have clinical utility in the context of (BRAF or MEK/ERK) inhibition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à une nouvelle méthode de traitement d'une néoplasie maligne. En particulier, la présente invention a trait au domaine du traitement d'une néoplasie chez des sujets qui en ont besoin et qui implique des protéines de la voie des MAPK/ERK (activée), comme les mélanomes BRAF et similaires. L'invention concerne également des compositions destinées à être utilisées dans un tel traitement, celles-ci utilisant des inhibiteurs de la pyruvate déshydrogénase kinase (PDK).
PCT/NL2013/050021 2012-01-16 2013-01-16 Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie WO2013109142A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586978P 2012-01-16 2012-01-16
US61/586,978 2012-01-16

Publications (1)

Publication Number Publication Date
WO2013109142A1 true WO2013109142A1 (fr) 2013-07-25

Family

ID=47682045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2013/050021 WO2013109142A1 (fr) 2012-01-16 2013-01-16 Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie

Country Status (1)

Country Link
WO (1) WO2013109142A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016025641A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et inhibiteur d'egfr et méthodes associées
WO2016025656A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et d'un inhibiteur de pi3k ou d'un double inhibiteur de pi3k/tor et procédés associés
WO2016025639A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur de erk et d'un agent chimiothérapeutique, et procédés associés
WO2016025648A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et d'un inhibiteur de raf et procédés associés
WO2016025649A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et d'un inhibiteur de dot1l et procédés associés
WO2016025652A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur de erk et d'un modulateur de la voie bcl-2 et méthodes associées
WO2016111991A1 (fr) * 2015-01-05 2016-07-14 Board Of Regent, The University Of Texas System Activité de la protéine kinase de phosphoglycerate kinase 1 en tant que cible pour le traitement et le diagnostic du cancer
US10525074B2 (en) 2013-03-14 2020-01-07 Epizyme, Inc. Combination therapy for treating cancer
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Citations (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044618A1 (fr) 1998-03-06 1999-09-10 Astrazeneca Ab Composes chimiques et utilisation de ces derniers pour elever l'activite du pyruvate-deshydrogenase
WO1999062506A1 (fr) 1998-05-29 1999-12-09 Astrazeneca Ab Utilisation de composes permettant d'elever l'activite de la pyruvate-deshydrogenase
WO2002024680A1 (fr) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
WO2002058687A2 (fr) 2001-01-25 2002-08-01 Board Of Regents, The University Of Texas System Inhibition de la erk reduisant ou prevenant a la fois la tolerance et la dependance aux analgesiques opioides et sensibilisation apres stimulation douloureuse
WO2003022840A1 (fr) 2001-09-05 2003-03-20 Smithkline Beecham Plc Derives de pyridine utilises comme inhibiteurs de raf kinase
AU2002356323A1 (en) 2001-12-24 2003-07-30 Catalyst Biomedica Limited Cancer-specific mutants of b-raf genes and uses thereof
WO2003077914A1 (fr) 2002-03-13 2003-09-25 Array Biopharma, Inc Utilisation de derives de benzimidazole alkyles n3 en tant qu'inhibiteurs de mek
US20040048861A1 (en) 2000-02-05 2004-03-11 Guy Bemis Compositions useful as inhibitors of ERK
US20040096855A1 (en) 2001-12-24 2004-05-20 Michael Stratton Genes
US20040102506A1 (en) 2000-02-05 2004-05-27 Michael Hale Pyrazole compositions useful as inhibitors of ERK
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
WO2005019451A1 (fr) 2003-08-22 2005-03-03 Japan Science And Technology Agency Construction d'acide nucleique pour exprimer l'inhibiteur de l'activite de pdk-1
US20050090536A1 (en) 2000-09-15 2005-04-28 Hale Michael R. Isoxazole compositions useful as inhibitors of ERK
WO2005051300A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs bicycliques de mek et leurs procedes de production
US20050159385A1 (en) 2003-12-19 2005-07-21 Mohapatra Shyam S. JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
WO2005089443A2 (fr) 2004-03-19 2005-09-29 The Penn State Research Foundation Procedes et compositions combinatoires pour le traitement de melanome
WO2005123696A1 (fr) 2004-06-15 2005-12-29 Astrazeneca Ab Quinazolones substitues en tant qu'agents anticancereux
WO2006003378A1 (fr) 2004-07-01 2006-01-12 Astrazeneca Ab Azine-carboxamides en tant qu'agent anti-cancer
WO2006024836A1 (fr) 2004-09-01 2006-03-09 Astrazeneca Ab Dérivés de quinazolinone et utilisation de ces dérivés en tant qu'inhibiteurs du b-raf
WO2006024834A1 (fr) 2004-08-31 2006-03-09 Astrazeneca Ab Dérivés de quinazolinone et utilisation de ces dérivés en tant qu'inhibiteurs du b-raf
WO2006042062A2 (fr) 2004-10-08 2006-04-20 The Johns Hopkins University Pyruvate deshydrogenase kinases utiles en tant que cibles therapeutiques pour le cancer et les maladies ischemiques
WO2006040568A1 (fr) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines en tant qu'inhibiteurs b-raf
WO2006053201A2 (fr) 2004-11-09 2006-05-18 Mount Sinai School Of Medicine Of New York University Traitement du cancer par inhibition simultanee de b-raf et restauration ou mimetisme de l'activite de p16 ink4a
WO2006067446A1 (fr) 2004-12-22 2006-06-29 Astrazeneca Ab Dérivés de pyridinecarboxamide employés en tant qu'agents anticancéreux
WO2006079791A1 (fr) 2005-01-25 2006-08-03 Astrazeneca Ab Composes chimiques
WO2007002325A1 (fr) 2005-06-22 2007-01-04 Plexxikon, Inc. Composes et methodes de modulation de la kinase et instructions afferentes
WO2007025090A2 (fr) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibiteurs de kinase mapk/erk
WO2007044084A2 (fr) 2005-05-18 2007-04-19 Array Biopharma Inc. Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2007076245A2 (fr) 2005-12-21 2007-07-05 Array Biopharma Inc. Nouveau sel hydrogenosulfate
WO2007083978A1 (fr) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Dérivés d'imidazopyridine inhibant l'activité de la protéine kinase, méthode de préparation de ces derniers et composition pharmaceutique les comprenant
US20070232610A1 (en) 2006-02-16 2007-10-04 Yongqi Deng Novel compounds that are ERK inhibitors
WO2007113505A2 (fr) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Milieu de culture contenant des inhibiteurs de kinase et utilisation de celui-ci
WO2008055236A2 (fr) 2006-10-31 2008-05-08 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase mapk/erk
WO2008115890A2 (fr) 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Inhibiteurs de mapk/erk kinase
WO2008120004A1 (fr) 2007-04-02 2008-10-09 Astrazeneca Ab Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer
WO2008124085A2 (fr) 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2009018238A1 (fr) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations
WO2009018233A1 (fr) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
WO2009026487A1 (fr) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Procédés et compositions pour induire une dérégulation de la phosphorylation de epha7 et de erk dans des cas de leucémies humaines aiguës
WO2009067767A2 (fr) 2007-11-26 2009-06-04 Katholieke Universiteit Leuven Radiothérapie ciblée
US20090181371A1 (en) 2005-07-13 2009-07-16 Samowitz Wade S Methods and compositions related to a braf mutation and microsatellite stability
US20090186379A1 (en) 2006-11-13 2009-07-23 Thomas David Reed ERK ligands and polynucleotides encoding ERK ligands
TW200934775A (en) 2007-11-12 2009-08-16 Takeda Pharmaceutical MAPK/ERK kinase inhibitors
WO2009146034A2 (fr) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
US20100004234A1 (en) 2004-09-27 2010-01-07 Kosan Biosciences Incorporated Specific kinase inhibitors
US20100004247A1 (en) 2007-12-12 2010-01-07 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
US20100130519A1 (en) 2007-04-13 2010-05-27 Stephen Robert Wedge Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
WO2010114928A2 (fr) 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions et utilisations associées
US20110038876A1 (en) 2007-06-18 2011-02-17 Robert Sun Heterocyclic compounds and use thereof as erk inhibitors
WO2011041152A1 (fr) 2009-09-30 2011-04-07 Schering Corporation Nouveaux composés inhibiteurs d'erk
US20110105521A1 (en) 2008-07-11 2011-05-05 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
US20110110916A1 (en) 2008-05-01 2011-05-12 Worman Howard J Methods for treating and/or preventing cardiomyopathies by erk or jnk inhibition
WO2011067356A2 (fr) 2009-12-03 2011-06-09 Novartis Ag Polymorphes d'un inhibiteur de mek
WO2011067348A2 (fr) 2009-12-03 2011-06-09 Novartis Ag Sels d'inhibiteurs de mek et leurs solvates
EP2332922A1 (fr) 2001-10-23 2011-06-15 Merck Serono S.A. Azoles N-substitués et leur utilisation en tant que modulateurs de MEK-1 et/ou ERK-2
WO2011081408A2 (fr) * 2009-12-28 2011-07-07 Celltrion Chemical Research Institute Dichloroacétate d'imatinib et agent anticancéreux le comprenant
WO2011095807A1 (fr) 2010-02-07 2011-08-11 Astrazeneca Ab Combinaisons d'inhibiteurs de mek et de hh
US20110207694A1 (en) 2005-05-03 2011-08-25 Luciano Rossetti Mammalian hypothalamic nutrient modulation of glucose metabolism
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
HRP20110892T1 (hr) 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
US20120004284A1 (en) 2008-09-02 2012-01-05 University Of Florida Research Foundation Pdk inhibitor compounds and methods of use thereof
WO2012008711A2 (fr) * 2010-07-15 2012-01-19 Celltrion Chemical Research Institute Dichloroacétate d'erlotinib et agent anticancéreux comprenant ce dernier

Patent Citations (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044618A1 (fr) 1998-03-06 1999-09-10 Astrazeneca Ab Composes chimiques et utilisation de ces derniers pour elever l'activite du pyruvate-deshydrogenase
WO1999062506A1 (fr) 1998-05-29 1999-12-09 Astrazeneca Ab Utilisation de composes permettant d'elever l'activite de la pyruvate-deshydrogenase
US20040048861A1 (en) 2000-02-05 2004-03-11 Guy Bemis Compositions useful as inhibitors of ERK
US20040102506A1 (en) 2000-02-05 2004-05-27 Michael Hale Pyrazole compositions useful as inhibitors of ERK
US20050090536A1 (en) 2000-09-15 2005-04-28 Hale Michael R. Isoxazole compositions useful as inhibitors of ERK
WO2002024680A1 (fr) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
WO2002058687A2 (fr) 2001-01-25 2002-08-01 Board Of Regents, The University Of Texas System Inhibition de la erk reduisant ou prevenant a la fois la tolerance et la dependance aux analgesiques opioides et sensibilisation apres stimulation douloureuse
AU2002248381A1 (en) 2001-01-25 2002-08-06 Board Of Regents, The University Of Texas System Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics
WO2003022840A1 (fr) 2001-09-05 2003-03-20 Smithkline Beecham Plc Derives de pyridine utilises comme inhibiteurs de raf kinase
EP2332922A1 (fr) 2001-10-23 2011-06-15 Merck Serono S.A. Azoles N-substitués et leur utilisation en tant que modulateurs de MEK-1 et/ou ERK-2
US20040096855A1 (en) 2001-12-24 2004-05-20 Michael Stratton Genes
AU2002356323A1 (en) 2001-12-24 2003-07-30 Catalyst Biomedica Limited Cancer-specific mutants of b-raf genes and uses thereof
WO2003077914A1 (fr) 2002-03-13 2003-09-25 Array Biopharma, Inc Utilisation de derives de benzimidazole alkyles n3 en tant qu'inhibiteurs de mek
WO2005019451A1 (fr) 2003-08-22 2005-03-03 Japan Science And Technology Agency Construction d'acide nucleique pour exprimer l'inhibiteur de l'activite de pdk-1
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
WO2005047542A1 (fr) 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Traitements inhibant le developpement et la progression de naevi et de melanomes presentant des mutations de braf
WO2005051300A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs bicycliques de mek et leurs procedes de production
US20050159385A1 (en) 2003-12-19 2005-07-21 Mohapatra Shyam S. JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
WO2005089443A2 (fr) 2004-03-19 2005-09-29 The Penn State Research Foundation Procedes et compositions combinatoires pour le traitement de melanome
US20050267060A1 (en) 2004-03-19 2005-12-01 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
WO2005123696A1 (fr) 2004-06-15 2005-12-29 Astrazeneca Ab Quinazolones substitues en tant qu'agents anticancereux
WO2006003378A1 (fr) 2004-07-01 2006-01-12 Astrazeneca Ab Azine-carboxamides en tant qu'agent anti-cancer
WO2006024834A1 (fr) 2004-08-31 2006-03-09 Astrazeneca Ab Dérivés de quinazolinone et utilisation de ces dérivés en tant qu'inhibiteurs du b-raf
WO2006024836A1 (fr) 2004-09-01 2006-03-09 Astrazeneca Ab Dérivés de quinazolinone et utilisation de ces dérivés en tant qu'inhibiteurs du b-raf
US20100004234A1 (en) 2004-09-27 2010-01-07 Kosan Biosciences Incorporated Specific kinase inhibitors
WO2006042062A2 (fr) 2004-10-08 2006-04-20 The Johns Hopkins University Pyruvate deshydrogenase kinases utiles en tant que cibles therapeutiques pour le cancer et les maladies ischemiques
US20090209618A1 (en) 2004-10-08 2009-08-20 Dang Chi V Pyruvate dehydrogenase kinases as therapeutic targets for cancer and ischemic diseases
WO2006040568A1 (fr) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines en tant qu'inhibiteurs b-raf
WO2006053201A2 (fr) 2004-11-09 2006-05-18 Mount Sinai School Of Medicine Of New York University Traitement du cancer par inhibition simultanee de b-raf et restauration ou mimetisme de l'activite de p16 ink4a
WO2006067446A1 (fr) 2004-12-22 2006-06-29 Astrazeneca Ab Dérivés de pyridinecarboxamide employés en tant qu'agents anticancéreux
WO2006079791A1 (fr) 2005-01-25 2006-08-03 Astrazeneca Ab Composes chimiques
US20110207694A1 (en) 2005-05-03 2011-08-25 Luciano Rossetti Mammalian hypothalamic nutrient modulation of glucose metabolism
WO2007044084A2 (fr) 2005-05-18 2007-04-19 Array Biopharma Inc. Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2007002325A1 (fr) 2005-06-22 2007-01-04 Plexxikon, Inc. Composes et methodes de modulation de la kinase et instructions afferentes
US20090181371A1 (en) 2005-07-13 2009-07-16 Samowitz Wade S Methods and compositions related to a braf mutation and microsatellite stability
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
WO2007025090A2 (fr) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibiteurs de kinase mapk/erk
HRP20110892T1 (hr) 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
WO2007076245A2 (fr) 2005-12-21 2007-07-05 Array Biopharma Inc. Nouveau sel hydrogenosulfate
WO2007083978A1 (fr) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Dérivés d'imidazopyridine inhibant l'activité de la protéine kinase, méthode de préparation de ces derniers et composition pharmaceutique les comprenant
US20070232610A1 (en) 2006-02-16 2007-10-04 Yongqi Deng Novel compounds that are ERK inhibitors
HK1117159A1 (en) 2006-02-16 2009-01-09 Schering Corporation Pyrrolidine derivatives as erk inhibitors
WO2007113505A2 (fr) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Milieu de culture contenant des inhibiteurs de kinase et utilisation de celui-ci
WO2008055236A2 (fr) 2006-10-31 2008-05-08 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase mapk/erk
US20090186379A1 (en) 2006-11-13 2009-07-23 Thomas David Reed ERK ligands and polynucleotides encoding ERK ligands
WO2008115890A2 (fr) 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Inhibiteurs de mapk/erk kinase
WO2008120004A1 (fr) 2007-04-02 2008-10-09 Astrazeneca Ab Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer
WO2008124085A2 (fr) 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
US20100130519A1 (en) 2007-04-13 2010-05-27 Stephen Robert Wedge Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
US20110038876A1 (en) 2007-06-18 2011-02-17 Robert Sun Heterocyclic compounds and use thereof as erk inhibitors
WO2009018238A1 (fr) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations
WO2009018233A1 (fr) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
WO2009026487A1 (fr) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Procédés et compositions pour induire une dérégulation de la phosphorylation de epha7 et de erk dans des cas de leucémies humaines aiguës
TW200934775A (en) 2007-11-12 2009-08-16 Takeda Pharmaceutical MAPK/ERK kinase inhibitors
WO2009067767A2 (fr) 2007-11-26 2009-06-04 Katholieke Universiteit Leuven Radiothérapie ciblée
US20100004247A1 (en) 2007-12-12 2010-01-07 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
WO2009146034A2 (fr) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
US20110110916A1 (en) 2008-05-01 2011-05-12 Worman Howard J Methods for treating and/or preventing cardiomyopathies by erk or jnk inhibition
US20110105521A1 (en) 2008-07-11 2011-05-05 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
US20120004284A1 (en) 2008-09-02 2012-01-05 University Of Florida Research Foundation Pdk inhibitor compounds and methods of use thereof
WO2010114928A2 (fr) 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions et utilisations associées
WO2011041152A1 (fr) 2009-09-30 2011-04-07 Schering Corporation Nouveaux composés inhibiteurs d'erk
WO2011067348A2 (fr) 2009-12-03 2011-06-09 Novartis Ag Sels d'inhibiteurs de mek et leurs solvates
WO2011067356A2 (fr) 2009-12-03 2011-06-09 Novartis Ag Polymorphes d'un inhibiteur de mek
WO2011081408A2 (fr) * 2009-12-28 2011-07-07 Celltrion Chemical Research Institute Dichloroacétate d'imatinib et agent anticancéreux le comprenant
WO2011095807A1 (fr) 2010-02-07 2011-08-11 Astrazeneca Ab Combinaisons d'inhibiteurs de mek et de hh
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
WO2012008711A2 (fr) * 2010-07-15 2012-01-19 Celltrion Chemical Research Institute Dichloroacétate d'erlotinib et agent anticancéreux comprenant ce dernier

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
AICHER ET AL., J. MED. CHEM., vol. 43, 2000, pages 236 - 249
ALBERT L. LEHNINGER: "Principles of Biochemistry", 1982, WORTH PUB, pages: 793 - 800
ALESSI ET AL., J BIOL CHEM., vol. 270, no. 46, 17 November 1995 (1995-11-17), pages 27489 - 94
ALLEN; MEYER, SEMIN ONCOL., vol. 30, no. 16, October 2003 (2003-10-01), pages 105 - 16
BIOORG MED CHEM LETT, vol. 21, no. 13, 1 July 2011 (2011-07-01), pages 4066 - 71
BOKEMEYER ET AL., KIDNEY INT., vol. 49, 1996, pages 1187
BOLLAG ET AL., NATURE, vol. 467, 2010, pages 596 - 9
CARR ET AL., PSYCHOPHARMACOLOGY (BERL)., vol. 201, no. 4, January 2009 (2009-01-01), pages 495 - 506
CLIN CANCER RES., 2011, Retrieved from the Internet <URL:www.ama-assn.org/resources/doc/usan/dabrafenib.pdf>
CURTIN ET AL., N ENGL J MED, vol. 353, 2005, pages 2135 - 47
DAVIES ET AL., BIOCHEM J., vol. 351, pages 95 - 105
DAVIES ET AL., NATURE, vol. 417, 2002, pages 949 - 54
DOWNEY ET AL., J BIOL CHEM., vol. 271, no. 35, 1996, pages 21005 - 21011
FAVATA, M. ET AL.: "Identification of a novel inhibitor of mitogen-activated protein kinase", J. BIOL. CHEM., vol. 273, 1998, pages 18623, XP002141538, DOI: doi:10.1074/jbc.273.29.18623
FECHER ET AL., CURR OPIN ONCOL, vol. 20, 2008, pages 183 - 189
FLAHERTY ET AL., N ENGL J MED, vol. 363, 2010, pages 809 - 19
FLAHERTY, NATURE REVIEWS: DRUG DISCOVERY, vol. 10, 2011, pages 811
HARRIS ET AL., ADV. ENZYME REGUL., vol. 41, 2001, pages 269 - 288
HENDERSON ET AL., MOL CANCER THER, vol. 9, July 2010 (2010-07-01), pages 1968
HOLNESS; SUGDEN, BIOCHEM. SOC. TRANS., vol. 31, 2003, pages 1143 - 1151
IKAWA, MOL CELL BIOL., vol. 8, no. 6, 1988, pages 2651 - 4
J. KLUZA ET AL: "Inactivation of the HIF-1 /PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-Oxidants", CANCER RESEARCH, vol. 72, no. 19, 1 October 2012 (2012-10-01), pages 5035 - 5047, XP055058978, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-0979 *
JAISWAL ET AL., MOL CELL BIOL., vol. 14, no. 10, 1994, pages 6944 - 53
JERANT ET AL., AM FAM PHYSICIAN, vol. 62, no. 2, 2000, pages 357 - 68,375-6,381-2
KATO ET AL., STRUCTURE, vol. 15, 2007, pages 992 - 1004
KATO ET AL., STRUCTURE, vol. 15, no. 8, August 2007 (2007-08-01), pages 992 - 1004
KLAUS P. HOEFLICH ET AL., CANCER RES., vol. 69, 1 April 2009 (2009-04-01), pages 3042 - 3051
KNOECHEL ET AL., BIOCHEMISTRY, vol. 45, 2006, pages 402 - 415
KOLOBOVA ET AL., BIOCHEM. J., vol. 358, 2001, pages 69 - 77
KOROTCHKINA; PATEL, J. BIOL. CHEM., vol. 276, 2001, pages 37223 - 37229
LEE ET AL., SEMINARS IN ONCOLOGY, vol. 30, October 2003 (2003-10-01), pages 105 - 106
LORUSSO ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 23, 2005, pages 5281 - 5293
LUCAS ET AL.: "Environmental Burden of Disease Series", vol. 13, 2006, WORLD HEALTH ORGANIZATION
MANN ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1480, 2000, pages 283 - 292
MARCH: "Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed.,", 1992, J. WILEY & SONS
MAYER, BIOCHEM SOC TRANS., vol. 31, no. 6, December 2003 (2003-12-01), pages 1165 - 7
MAYERS ET AL., BIOCHEM. SOC. TRANS., vol. 33, 2005, pages 367 - 370
PARKIN ET AL., CA CANCER J CLIN, vol. 55, no. 2, 2005, pages 74 - 108
PATEL; ROCHE, FASEB J., vol. 4, 1990, pages 3224 - 3233
PEYSSONNAUX ET AL., BIOL CELL, vol. 93, no. 1-2, 2001, pages 53 - 62
POPOV ET AL., ADV. SECOND MESSENGER PHOSPHOPROTEIN RES., vol. 31, 1997, pages 105 - 111
POULIKAKOS ET AL., SCIENCE SIGNALING, vol. 4, no. 166, 2011, pages 1
REED, J. BIOL. CHEM., vol. 276, 2001, pages 28329 - 28336
ROBERTS ET AL., ONCOGENE, vol. 26, 2007, pages 3291
SAMBROOK; RUSSEL: "Molecular Cloning: A Laboratory Manual 3rd ed.,", 2001, COLD SPRING HARBOR LABORATORY PRESS
SINGLETON ET AL.: "Dictionary of Microbiology and Molecular Biology 2nd ed.,", 1994, J. WILEY & SONS
SOLIT ET AL., N ENGL J MED, vol. 364, 2011, pages 8
TECLE ET AL., MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 1, 1 January 2009 (2009-01-01), pages 226 - 229
TSAI ET AL., PNAS, vol. 105, no. 8, 2008, pages 3041
WHITEHOUSE ET AL., BIOCHEM J, vol. 141, 1974, pages 761 - 774
WILLIAMS; ROBERTS, CANCER METASTASIS REV., vol. 13, no. 1, 1994, pages 105 - 16
Y-C SHEN ET AL: "Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma", BRITISH JOURNAL OF CANCER, vol. 108, no. 1, 20 December 2012 (2012-12-20), pages 72 - 81, XP055058980, ISSN: 0007-0920, DOI: 10.1038/bjc.2012.559 *
ZHANG ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, 2000, pages 2825 - 2828

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10525074B2 (en) 2013-03-14 2020-01-07 Epizyme, Inc. Combination therapy for treating cancer
WO2016025641A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et inhibiteur d'egfr et méthodes associées
WO2016025656A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et d'un inhibiteur de pi3k ou d'un double inhibiteur de pi3k/tor et procédés associés
WO2016025639A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur de erk et d'un agent chimiothérapeutique, et procédés associés
WO2016025648A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et d'un inhibiteur de raf et procédés associés
WO2016025649A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et d'un inhibiteur de dot1l et procédés associés
WO2016025652A1 (fr) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur de erk et d'un modulateur de la voie bcl-2 et méthodes associées
WO2016111991A1 (fr) * 2015-01-05 2016-07-14 Board Of Regent, The University Of Texas System Activité de la protéine kinase de phosphoglycerate kinase 1 en tant que cible pour le traitement et le diagnostic du cancer
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Similar Documents

Publication Publication Date Title
WO2013109142A1 (fr) Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
Patel et al. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways
Zhang et al. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1
Qian et al. Micro RNA‐26a Promotes Tumor Growth and Angiogenesis in Glioma by Directly Targeting Prohibitin
Li et al. miR-22 targets the 3′ UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy
Zhu et al. MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3
Zhang et al. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1 Retraction in/10.3892/ijo. 2023.5525
Han et al. PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells
Li et al. Tumor suppressor role of miR-217 in human epithelial ovarian cancer by targeting IGF1R
Wang et al. LncRNA SNHG3 regulates laryngeal carcinoma proliferation and migration by modulating the miR-384/WEE1 axis
Wang et al. Girdin regulates the proliferation and apoptosis of pancreatic cancer cells via the PI3K/Akt signalling pathway
Yang et al. miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and suppresses tumorigenesis in osteosarcoma via Wnt/β-catenin signaling pathway
Yan et al. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression
Ido et al. Acute activation of AMP-activated protein kinase prevents H2O2-induced premature senescence in primary human keratinocytes
Zhou et al. Protein kinase CK2α maintains extracellular signal-regulated kinase (ERK) activity in a CK2α kinase-independent manner to promote resistance to inhibitors of RAF and MEK but not ERK in BRAF mutant melanoma
Sharma et al. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of V600EB-RAF in melanoma
Sarkar et al. Insulin enhances migration and invasion in prostate cancer cells by up-regulation of FOXC2
US20220133721A1 (en) Method for treating cancer
Liu et al. M6A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer
Liu et al. miR-29a inhibits human retinoblastoma progression by targeting STAT3
Brucker et al. FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death
Noh et al. Aurora kinases are essential for PKC-induced invasion and matrix metalloproteinase-9 expression in MCF-7 breast cancer cells
Jiang et al. miR‑150 promotes the proliferation and migration of non‑small cell lung cancer cells by regulating the SIRT2/JMJD2A signaling pathway
Zhu et al. miR-142-5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA
Zhang et al. MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13703481

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13703481

Country of ref document: EP

Kind code of ref document: A1